dupilumab
regeneron,sanofi
['dupixent', 'dupilumab', '$sny', '$regn']
$regn $sny dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis 